FNY Partners Fund LP Takes $293,000 Position in Novadaq Technologies Inc (NVDQ)

FNY Partners Fund LP acquired a new position in shares of Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,000 shares of the medical research company’s stock, valued at approximately $293,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vivaldi Capital Management LLC acquired a new position in shares of Novadaq Technologies during the 2nd quarter worth about $133,397,000. Vivaldi Asset Management LLC acquired a new position in shares of Novadaq Technologies during the 2nd quarter worth about $1,390,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Novadaq Technologies during the 2nd quarter worth about $4,326,000. JPMorgan Chase & Co. increased its stake in shares of Novadaq Technologies by 4.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,308,769 shares of the medical research company’s stock worth $62,219,000 after purchasing an additional 243,261 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Novadaq Technologies during the 2nd quarter worth about $4,031,000. Institutional investors own 75.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://transcriptdaily.com/2017/09/12/fny-partners-fund-lp-takes-293000-position-in-novadaq-technologies-inc-nvdq.html.

NVDQ has been the topic of several recent analyst reports. Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Novadaq Technologies in a research note on Friday, June 2nd. Craig Hallum lowered shares of Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 price objective on the stock. in a research note on Monday, June 19th. Canaccord Genuity lowered shares of Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 price objective on the stock. in a research note on Monday, July 10th. Wedbush lowered shares of Novadaq Technologies from an “outperform” rating to a “neutral” rating in a research note on Monday, June 19th. Finally, Zacks Investment Research lowered shares of Novadaq Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $11.86.

Shares of Novadaq Technologies Inc (NVDQ) traded up inf% on Tuesday, reaching $11.75. 395,280 shares of the company were exchanged. Novadaq Technologies Inc has a 12-month low of $5.84 and a 12-month high of $12.74. The firm’s market capitalization is $679.41 million. The company’s 50 day moving average is $11.68 and its 200 day moving average is $9.03.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Institutional Ownership by Quarter for Novadaq Technologies (NASDAQ:NVDQ)

Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply